{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:05:59Z","timestamp":1792717559281,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"15","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>European clinical guidelines recommend that patients with atherosclerotic cardiovascular disease (ASCVD), including ischaemic heart disease (IHD), stroke, and peripheral arterial disease (PAD), are prescribed lipid lowering treatment (LLT) and treated to target low-density lipoprotein cholesterol (LDL-C) levels. This study aimed to document trends in ASCVD, including treatment, monitoring, and achievement of target LDL-C.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>A retrospective observational population study was performed using linked healthcare data (2010\u201322). Over the study period, the number of patients with ASCVD increased from 181 153 to 207 747 (8882 to 9398 per 100 000). The proportion of patients prescribed LLT decreased from 75.3% in 2010 to 67.1% in 2022; high-intensity statin therapy increased from 9.4 to 25.2%, while non-high-intensity statin therapy decreased from 59.6 to 38.2%. The prescription of high-intensity statin therapy was consistently higher amongst patients with IHD (10.9% in 2010 increasing to 28.0% in 2022) than in patients with stroke (4.7\u201321.6%) or PAD (3.9\u201310.6%).<\/jats:p>\n                  <jats:p>The proportion of cases with documented LDL-C decreased from 58.0% in 2010 to 49.3% in 2022. Of those with documented LDL-C in 2022, 44.0% achieved LDL-C &amp;lt; 1.8 mmol\/L, including 45.2% of those with IHD, 42.0% of those with stroke, and only 32.8% of those with PAD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Prescription of LLT, including high-intensity statin therapy, documentation of LDL-C, and achievement of target LDL-C levels was relatively low, especially in PAD patients. Although target achievement in \u2018tested patients\u2019 increased over time, the proportion of patients undergoing lipid testing declined. More rigorous lipid management requires prioritisation, especially for PAD and stroke patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwae233","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T10:44:51Z","timestamp":1721645091000},"page":"1778-1789","source":"Crossref","is-referenced-by-count":13,"title":["Trends in atherosclerotic cardiovascular disease and lipid management: a population-level observational cohort study in Wales"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4885-637X","authenticated-orcid":false,"given":"Daniel E","family":"Harris","sequence":"first","affiliation":[{"name":"Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea University , Singleton Park, Swansea , , SA2 8PP","place":["UK"]},{"name":"Tritech Institute, Hywel Dda University Health Board , Llanelli , , SA14 9TD","place":["UK"]},{"name":"Pharmacy Department, Hywel Dda University Health Board, Prince Phillip Hospital , Llanelli , , SA14 8QF","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9700-7158","authenticated-orcid":false,"given":"Daniel","family":"King","sequence":"additional","affiliation":[{"name":"Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea University , Singleton Park, Swansea , , SA2 8PP","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0814-0801","authenticated-orcid":false,"given":"Ashley","family":"Akbari","sequence":"additional","affiliation":[{"name":"Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea University , Singleton Park, Swansea , , SA2 8PP","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0710-0947","authenticated-orcid":false,"given":"Mike","family":"Gravenor","sequence":"additional","affiliation":[{"name":"Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea University , Singleton Park, Swansea , , SA2 8PP","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Tritech Institute, Hywel Dda University Health Board , Llanelli , , SA14 9TD","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8995-8199","authenticated-orcid":false,"given":"Clive","family":"Weston","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hywel Dda University Health Board, Glangwili Hospital , Carmarthen , , SA31 2AF","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2496-3832","authenticated-orcid":false,"given":"Chris","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Tritech Institute, Hywel Dda University Health Board , Llanelli , , SA14 9TD","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4918-8174","authenticated-orcid":false,"given":"Leighton","family":"Phillips","sequence":"additional","affiliation":[{"name":"Tritech Institute, Hywel Dda University Health Board , Llanelli , , SA14 9TD","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6926-2947","authenticated-orcid":false,"given":"Julian","family":"Halcox","sequence":"additional","affiliation":[{"name":"Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea University , Singleton Park, Swansea , , SA2 8PP","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"2024111108002513000_zwae233-B1","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"2024111108002513000_zwae233-B2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"2024111108002513000_zwae233-B3","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists' (CTT) Collaboration","year":"2015","journal-title":"Lancet"},{"key":"2024111108002513000_zwae233-B4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2024111108002513000_zwae233-B5","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024111108002513000_zwae233-B6","author":"National Institute for Health and Care Excellence"},{"key":"2024111108002513000_zwae233-B7","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"European Association for Cardiovascular Prevention & Rehabilitation 1","year":"2011","journal-title":"Eur Heart J"},{"key":"2024111108002513000_zwae233-B8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1472-6963-9-157","article-title":"The SAIL databank: building a national architecture for e-health research and evaluation","volume":"9","author":"Ford","year":"2009","journal-title":"BMC Health Serv Res"},{"key":"2024111108002513000_zwae233-B9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-6947-9-3","article-title":"The SAIL databank: linking multiple health and social care datasets","volume":"9","author":"Lyons","year":"2009","journal-title":"BMC Med Inform Decis Mak"},{"key":"2024111108002513000_zwae233-B10","author":"SAIL"},{"key":"2024111108002513000_zwae233-B11","author":"Patient Episode Database for Wales"},{"key":"2024111108002513000_zwae233-B12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1177\/2047487319899626","article-title":"Trends in peripheral arterial disease incidence and mortality in EU15+ countries 1990\u20132017","volume":"28","author":"Goodall","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2024111108002513000_zwae233-B13","doi-asserted-by":"crossref","first-page":"e018184","DOI":"10.1136\/bmjopen-2017-018184","article-title":"Time trends in peripheral artery disease incidence, prevalence and secondary preventive therapy: a cohort study in the health improvement network in the UK","volume":"8","author":"Cea-Soriano","year":"2018","journal-title":"BMJ Open"},{"key":"2024111108002513000_zwae233-B14","doi-asserted-by":"crossref","first-page":"e000269","DOI":"10.1136\/bmjopen-2011-000269","article-title":"UK stroke incidence, mortality and cardiovascular risk management 1999\u20132008: time-trend analysis from the general practice research database","volume":"1","author":"Lee","year":"2011","journal-title":"BMJ Open"},{"key":"2024111108002513000_zwae233-B15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ehjqcco\/qcaa076","article-title":"Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990\u20132017: results from the Global Burden of Disease Study 2017","volume":"8","author":"Zhou","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2024111108002513000_zwae233-B16","doi-asserted-by":"crossref","first-page":"e072098","DOI":"10.1136\/bmj-2022-072098","article-title":"Estimated impact from the withdrawal of primary care financial incentives on selected indicators of quality of care in Scotland: controlled interrupted time series analysis","volume":"380","author":"Morales","year":"2023","journal-title":"BMJ"},{"key":"2024111108002513000_zwae233-B17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41591-022-02158-7","article-title":"The impact of the COVID-19 pandemic on cardiovascular disease prevention and management","volume":"29","author":"Dale","year":"2023","journal-title":"Nat Med"},{"key":"2024111108002513000_zwae233-B18","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1177\/2047487320914115","article-title":"Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: a population-level observational cohort study","volume":"28","author":"Harris","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2024111108002513000_zwae233-B19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.08.013","article-title":"Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II","volume":"266","author":"Gitt","year":"2017","journal-title":"Atherosclerosis"},{"key":"2024111108002513000_zwae233-B20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","author":"De Backer","year":"2019","journal-title":"Atherosclerosis"},{"key":"2024111108002513000_zwae233-B21","doi-asserted-by":"crossref","first-page":"ep006460","DOI":"10.1161\/JAHA.117.006460","article-title":"Lipid testing and statin dosing after acute myocardial infarction","volume":"7","author":"Wang","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2024111108002513000_zwae233-B22","doi-asserted-by":"crossref","first-page":"e0186861","DOI":"10.1371\/journal.pone.0186861","article-title":"Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? Data from a multicenter registry cohort study in Taiwan","volume":"12","author":"Yeh","year":"2017","journal-title":"PLoS One"},{"key":"2024111108002513000_zwae233-B23","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the ultinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2024111108002513000_zwae233-B24","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/eurjpc\/zwad022","article-title":"The use of evidence-based medical therapy in patients with critical limb-threatening ischaemia","volume":"30","author":"Bager","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2024111108002513000_zwae233-B25","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2024111108002513000_zwae233-B26","author":"The National Institute for Health and Care Excellence"},{"key":"2024111108002513000_zwae233-B27","author":"The National Institute for health and Care Excellence"},{"key":"2024111108002513000_zwae233-B28","author":"All Wales Medicines Strategy Group"},{"key":"2024111108002513000_zwae233-B29","author":"National Institute for Health and care Excellence"},{"key":"2024111108002513000_zwae233-B30","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"key":"2024111108002513000_zwae233-B31","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMp1002305","article-title":"Thinking outside the pillbox\u2014medication adherence as a priority for health care reform","volume":"362","author":"Cutler","year":"2010","journal-title":"N Engl J Med"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwae233\/58876953\/zwae233.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/15\/1778\/60584717\/zwae233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/15\/1778\/60584717\/zwae233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T08:00:43Z","timestamp":1731312043000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/31\/15\/1778\/7717842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":31,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,7,23]]},"published-print":{"date-parts":[[2024,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwae233","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,7,23]]}}}